Home › Therapeutic areas › Neurology › Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (9 companies)
Companies with an active program in Duchenne Muscular Dystrophy.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| CAPR | Capricor Therapeutics | Infectious DiseaseNeurology Rare | 1 | NDA Submitted | $523M | 2 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | 5 | NDA Submitted | $3.39B | 10 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 1 | Approved | $25.1B | 15 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 1 | Phase 3 | $184M | 5 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | $1.85B | 5 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $296M | 5 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 4 | Approved | $1.91B | 11 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | 1 | Phase 3 | $736M | 6 |
| WVE | Wave Life Sciences | MetabolicNeurology+1 Rare | 1 | Phase 2 | $665M | 5 |
No companies match.